CollPlant Biotechnologies Ltd. Sponsored ADR (NASDAQ:CLGN) Short Interest Update

CollPlant Biotechnologies Ltd. Sponsored ADR (NASDAQ:CLGN) saw a significant growth in short interest in August. As of August 31st, there was short interest totaling 131,118 shares, a growth of 498.5% from the August 15th total of 21,907 shares. Approximately 10.0% of the company’s stock are short sold. Based on an average daily volume of 17,402,039 shares, the short-interest ratio is currently 0.0 days.

CollPlant Biotechnologies Trading Up 3.8%

Shares of CLGN stock opened at $3.54 on Friday. The company has a market capitalization of $5.10 million, a P/E ratio of -0.24 and a beta of 1.79. CollPlant Biotechnologies has a 12 month low of $2.64 and a 12 month high of $31.80. The stock has a 50 day moving average of $3.32 and a two-hundred day moving average of $4.09.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of CollPlant Biotechnologies in a research report on Friday, September 4th. One investment analyst has rated the stock with a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Reduce” and an average price target of $120.00.

Institutional Trading of CollPlant Biotechnologies

An institutional investor recently raised its position in CollPlant Biotechnologies stock. Pinnacle Associates Ltd. boosted its holdings in shares of CollPlant Biotechnologies Ltd. Sponsored ADR (NASDAQ:CLGN) by 9.9% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 557,193 shares of the company’s stock after purchasing an additional 50,000 shares during the period. Pinnacle Associates Ltd. owned 4.36% of CollPlant Biotechnologies worth $780,000 as of its most recent SEC filing. Institutional investors and hedge funds own 21.69% of the company’s stock.

CollPlant Biotechnologies Company Profile

CollPlant Biotechnologies Ltd. (NASDAQ: CLGN) is a regenerative medicine company that develops and commercializes recombinant human collagen (rhCollagen) and 3D bioprinting technologies for medical and aesthetic applications. The company’s proprietary plant-based rhCollagen is produced using genetically engineered tobacco plants to provide a scalable, animal-free source of human collagen that meets regulatory standards.

CollPlant’s product portfolio includes Vergenix™ wound care matrices and dermal fillers for aesthetic and reconstructive purposes, as well as a range of bioinks designed for 3D bioprinting of soft and hard tissues.